Home News & Media Press Releases

Recent Pfizer Press Releases

  • Pfizer Obtains $2.15 Billion Settlement from Teva and Sun for Infringement of Protonix® Patent
    6/12/13 7:49 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today a $2.15 billion settlement reached with Teva Pharmaceuticals Industries, Limited and Sun Pharmaceutical Industries, Limited for patent-infringement damages resulting from their "at-risk” launches of generic Protonix® in the United States. The settlement comes after a nearly 10-year legal battle in which Pfizer and Nycomed (now part of Takeda) sought to enforce the patent for its blockbuster acid reflux medicine.more...
  • Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
    6/6/13 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, President and General Manager, Specialty Care and Oncology, at the Goldman Sachs 34th Annual Global Healthcare Conference on Thursday, June 13, 2013 at 8:40 a.m. Pacific Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Goldman Sachs 34th Annual Global Healthcare Conference”more...
  • Americans Believe Their Communities Are Ill-Prepared For Aging Population, New Survey Reveals; Survey Shows A Fear Of Getting Old Due To Health And Financial Concerns
    6/5/13 7:00 am EDT

    Pfizer and Generations United Challenge People and Communities to Define How They Want to Get Old

    NEW YORK--(BUSINESS WIRE)--Nearly nine out of ten people who live in the U.S. believe they will live a long life, yet 40 percent believe being old is something to fear due to potential health and financial concerns, according to the second annual Get Old survey. Despite rising rates of chronic disease estimated to affect nearly half (49%) the U.S. population by 2025, survey respondents expressed a surprising degree of comfort with the current state of theirmore...
  • Pfizer Prices $4.0 Billion Debt Offering
    5/28/13 5:58 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of five tranches of notes: $750,000,000 aggregate principal amount of 0.900% notes due 2017 $1,000,000,000 aggregate principal amount of 1.500% notes due 2018 $500,000,000 aggregate principal amount of floating rate notes due 2018 $1,000,000,000 aggregate principal amount of 3.000% notes due 2023more...
  • Pfizer Announces Plan for Split-Off of Zoetis
    5/22/13 8:00 am EDT
    • Provides Pfizer shareholders an option for a tax-free exchange
    • Better positions Pfizer to focus on its core business as an innovative biopharmaceutical company
    • The completion of the full separation of Zoetis expected to be accretive to Pfizer’s EPS beginning in 2014
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its intention to split off its remaining interest in Zoetis Inc. (NYSE: ZTS), through an exchange offer. Zoetis, formerly Pfizer’s animal health business, completed its initial public offering (IPO) in February 2013. In the exchange offer, Pfizer shareholders can exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis common stock owned by Pfizer. The exchange offer ismore...
  • Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility
    5/20/13 5:01 pm EDT

    Pfizer to Continue Evaluation of Inotuzumab Ozogamicin in Other Hematologic Malignancies

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who are not candidates for intensive high-dose chemotherapy. In this study, inotuzumab ozogamicin was administered on a once-a-month schedule in combination withmore...
  • Pfizer Announces 11 Abstracts for Tofacitinib to Be Presented at the European League Against Rheumatism (EULAR) 2013 Annual Meeting
    5/13/13 8:00 am EDT

    Additional Analyses Further Evaluate Safety and Efficacy of Tofacitinib in Rheumatoid Arthritis

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that 11 abstracts for tofacitinib will be presented at the European League Against Rheumatism (EULAR) 2013 Annual Meeting being held June 12-15 in Madrid, Spain. The brand name for tofacitinib is XELJANZ® (ZEL’ JANS’). Highlights include: Comparison of monotherapy vs. combination therapy with tofacitinib A meta-analysis of four Phase 3 trials (ORAL Sync, Standard, Scanmore...
  • Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
    5/8/13 4:00 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Morgan Stanley 2013 R&D Seminar: Reigniting Pharma on Friday, May 10, 2013 at 11:00 a.m. Eastern Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley 2013 R&D Seminar: Reigniting Pharmamore...
  • Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation
    5/6/13 5:27 pm EDT

    • Subgroup analysis demonstrates that the treatment effects of Eliquis® (apixaban) vs. warfarin, across a broad range of warfarin control, are consistent with primary results of ARISTOTLE 
    • ARISTOTLE studied Eliquis vs. warfarin for the reduction of the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation

    Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from this subanalysis showed that the reductions in stroke or systemic embolism, number of  major bleeding events and mortality demonstrated with Eliquis® (apixaban) compared to warfarin in the ARISTOTLE trial were consistent acrossmore...
  • Facing Off Against Counterfeit Online Pharmacies: Pfizer Launches New Purchasing Website To Help Alleviate the Guesswork Around Buying Legitimate Viagra® (sildenafil citrate) Online
    5/6/13 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--To meet the needs of consumers who are increasingly going online to purchase prescription medications, Pfizer today launched Viagra® home delivery, a new prescription-fulfillment website for Viagra® (sildenafil citrate) tablets, Pfizer’s most counterfeited medicine. The site, which is powered by CVS/pharmacy and accessible through Viagra.com, offers men with erectile dysfunction (ED) an opportunity to purchase Viagra online (with a validmore...
Business Wire NewsHQ℠